SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 14D9 - Solicitation, recommendation statements:
SEC Accession No. 0001193125-22-295926
Filing Date
2022-12-01
Accepted
2022-12-01 07:38:30
Documents
5

Document Format Files

Seq Description Document Type Size
1 SC 14D9 d212100dsc14d9.htm SC 14D9 494713
2 EX-99.(E)(C) d212100dex99ec.htm EX-99.(E)(C) 91340
3 EX-99.(E)(Q) d212100dex99eq.htm EX-99.(E)(Q) 25923
4 EX-99.(E)(R) d212100dex99er.htm EX-99.(E)(R) 28087
5 GRAPHIC g212100g84k91.jpg GRAPHIC 4595
  Complete submission text file 0001193125-22-295926.txt   648181
Mailing Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filed by) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 14D9
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Subject) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 14D9 | Act: 34 | File No.: 005-91186 | Film No.: 221437324
SIC: 2836 Biological Products, (No Diagnostic Substances)